McKesson Again Boosts Outlook After 2Q Revenue Jumps 10%

Dow Jones

Nov 06

By Paul Ziobro

McKesson again raised its adjusted profit outlook for the year after revenue rose 10% in the second quarter, boosted by higher prescription volumes and growth in distribution of oncology and multispecialty products.

The pharmaceutical distributor on Wednesday reported a profit of $1.11 billion, or $8.92 a share, compared with $241 million, or $1.87 a share, a year ago.

Adjusted earnings were $9.86 a share. Analysts polled by FactSet expected $9.03 a share.

Revenue rose about 10% to $103.15 billion, short of analyst estimates for $104.14 billion. The company said growth was led by its North American pharmaceutical segment, where it logged more prescription volumes. Acquisitions in its Oncology and Multispecialty segment also provided a boost.

The company said its bottom-line boost came from operational growth across its businesses, including contributions from acquisitions, the sale of an investment and market decisions within the U.S. Oncology Network, among other items.

McKesson now expects adjusted per-share earnings between $38.35 and $38.85, compared to its prior view of $38.05 to $38.55.

Write to Paul Ziobro at paul.ziobro@wsj.com

(END) Dow Jones Newswires

November 05, 2025 16:56 ET (21:56 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581001117"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581001117\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581001117?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 05:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581001117","market":"sh","top_or_hot":-1,"title":"McKesson Again Boosts Outlook After 2Q Revenue Jumps 10%","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Paul Ziobro \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  McKesson again raised its adjusted profit outlook for the year after revenue rose 10% in the second quarter, boosted by higher prescription volumes and growth in distribution of oncology and multispecialty products. \n</p>\n<p>\n  The pharmaceutical distributor on Wednesday reported a profit of $1.11 billion, or $8.92 a share, compared with $241 million, or $1.87 a share, a year ago. \n</p>\n<p>\n  Adjusted earnings were $9.86 a share. Analysts polled by FactSet expected $9.03 a share. \n</p>\n<p>\n  Revenue rose about 10% to $103.15 billion, short of analyst estimates for $104.14 billion. The company said growth was led by its <a href=\"https://laohu8.com/S/FNCSF\">North American</a> pharmaceutical segment, where it logged more prescription volumes. Acquisitions in its Oncology and Multispecialty segment also provided a boost. \n</p>\n<p>\n  The company said its bottom-line boost came from operational growth across its businesses, including contributions from acquisitions, the sale of an investment and market decisions within the U.S. Oncology Network, among other items. \n</p>\n<p>\n  McKesson now expects adjusted per-share earnings between $38.35 and $38.85, compared to its prior view of $38.05 to $38.55. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 05, 2025 16:56 ET (21:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>McKesson Again Boosts Outlook After 2Q Revenue Jumps 10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMcKesson Again Boosts Outlook After 2Q Revenue Jumps 10%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-06 05:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Paul Ziobro \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  McKesson again raised its adjusted profit outlook for the year after revenue rose 10% in the second quarter, boosted by higher prescription volumes and growth in distribution of oncology and multispecialty products. \n</p>\n<p>\n  The pharmaceutical distributor on Wednesday reported a profit of $1.11 billion, or $8.92 a share, compared with $241 million, or $1.87 a share, a year ago. \n</p>\n<p>\n  Adjusted earnings were $9.86 a share. Analysts polled by FactSet expected $9.03 a share. \n</p>\n<p>\n  Revenue rose about 10% to $103.15 billion, short of analyst estimates for $104.14 billion. The company said growth was led by its <a href=\"https://laohu8.com/S/FNCSF\">North American</a> pharmaceutical segment, where it logged more prescription volumes. Acquisitions in its Oncology and Multispecialty segment also provided a boost. \n</p>\n<p>\n  The company said its bottom-line boost came from operational growth across its businesses, including contributions from acquisitions, the sale of an investment and market decisions within the U.S. Oncology Network, among other items. \n</p>\n<p>\n  McKesson now expects adjusted per-share earnings between $38.35 and $38.85, compared to its prior view of $38.05 to $38.55. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 05, 2025 16:56 ET (21:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MCK","symbol_name":"麦克森药物批发","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2581001117","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581001117","pubTimestamp":1762379760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"McKesson again raised its adjusted profit outlook for the year after revenue rose 10% in the second quarter, boosted by higher prescription volumes and growth in distribution of oncology and multispecialty products.The pharmaceutical distributor on Wednesday reported a profit of $1.11 billion, or $8.92 a share, compared with $241 million, or $1.87 a share, a year ago.Adjusted earnings were $9.86 a share. Analysts polled by FactSet expected $9.03 a share.Revenue rose about 10% to $103.15 billion, short of analyst estimates for $104.14 billion. The company said growth was led by its North American pharmaceutical segment, where it logged more prescription volumes. Acquisitions in its Oncology and Multispecialty segment also provided a boost.The company said its bottom-line boost came from operational growth across its businesses, including contributions from acquisitions, the sale of an investment and market decisions within the U.S. Oncology Network, among other items.McKesson now expect","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MCK":"麦克森药物批发"},"translate_title":"McKesson在第二季度收入增长10%后再次上调前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MCK":1.5},"content_text":"By Paul Ziobro \n\n\n \n\n\n  McKesson again raised its adjusted profit outlook for the year after revenue rose 10% in the second quarter, boosted by higher prescription volumes and growth in distribution of oncology and multispecialty products. \n\n\n  The pharmaceutical distributor on Wednesday reported a profit of $1.11 billion, or $8.92 a share, compared with $241 million, or $1.87 a share, a year ago. \n\n\n  Adjusted earnings were $9.86 a share. Analysts polled by FactSet expected $9.03 a share. \n\n\n  Revenue rose about 10% to $103.15 billion, short of analyst estimates for $104.14 billion. The company said growth was led by its North American pharmaceutical segment, where it logged more prescription volumes. Acquisitions in its Oncology and Multispecialty segment also provided a boost. \n\n\n  The company said its bottom-line boost came from operational growth across its businesses, including contributions from acquisitions, the sale of an investment and market decisions within the U.S. Oncology Network, among other items. \n\n\n  McKesson now expects adjusted per-share earnings between $38.35 and $38.85, compared to its prior view of $38.05 to $38.55. \n\n\n \n\n\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 16:56 ET (21:56 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}